Goldman Sachs Downgrades Biogen (BIIB) to Neutral, Removes from CL List

May 1, 2013 7:20 AM EDT Send to a Friend
Get Alerts BIIB Hot Sheet
Price: $414.13 --0%

Rating Summary:
    20 Buy, 9 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 9 | Down: 10 | New: 4
Trade BIIB Now!
Join SI Premium – FREE
Goldman Sachs downgraded Biogen (NASDAQ: BIIB) from Conviction Buy to Neutral with a price target of $215.00 (from $211.00), saying they prefer Amgen (NASDAQ: AMGN) which was added upgraded and added to the Conviction Buy List.

"We continue to view BIIB as a solid growth story within large-cap biotech, driven by what is proving to be a strong launch of new oral multiple sclerosis (MS) drug Tecfidera. However, we now see risk/reward as balanced," analyst Terence Flynn said.

While downgrading, Goldman raised FY 2013 EPS estimates on Biogen from $7.77 to $8.09, raised FY 2014 EPS from $10.39 to $10.43 and FY 2015 was trimmed from $13.33 to $13.24.

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $218.93 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst EPS Change, Analyst PT Change, Downgrades, Hot Downgrades

Related Entities

Goldman Sachs Conviction Buy List, Goldman Sachs

Add Your Comment